Our top pick for
Vericel Corporation is a biotechnology business based in the US. Vericel Corporation shares (VCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Vericel Corporation employs 241 staff and has a trailing 12-month revenue of around USD$118.3 million.
Since the stock market crash in March caused by coronavirus, Vericel Corporation's share price has had significant positive movement.
Its last market close was USD$25.67, which is 25.15% up on its pre-crash value of USD$19.215 and 278.61% up on the lowest point reached during the March crash when the shares fell as low as USD$6.78.
If you had bought USD$1,000 worth of Vericel Corporation shares at the start of February 2020, those shares would have been worth USD$438.67 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,521.72.
|Latest market close||USD$25.67|
|52-week range||USD$6.78 - USD$26.22|
|50-day moving average||USD$21.4925|
|200-day moving average||USD$17.2024|
|Wall St. target price||USD$29.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.003|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-15)||N/A|
|1 month (2020-10-26)||26.20%|
|3 months (2020-08-22)||N/A|
|6 months (2020-05-22)||N/A|
|1 year (2019-11-22)||N/A|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
Valuing Vericel Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vericel Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vericel Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2579x. In other words, Vericel Corporation shares trade at around 2579x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Vericel Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.5 million.
The EBITDA is a measure of a Vericel Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$118.3 million|
|Gross profit TTM||USD$80.3 million|
|Return on assets TTM||-0.3%|
|Return on equity TTM||0.14%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 4.2 million Vericel Corporation shares held short by investors – that's known as Vericel Corporation's "short interest". This figure is 0.5% down from 4.2 million last month.
There are a few different ways that this level of interest in shorting Vericel Corporation shares can be evaluated.
Vericel Corporation's "short interest ratio" (SIR) is the quantity of Vericel Corporation shares currently shorted divided by the average quantity of Vericel Corporation shares traded daily (recently around 458848.52780807). Vericel Corporation's SIR currently stands at 9.17. In other words for every 100,000 Vericel Corporation shares traded daily on the market, roughly 9170 shares are currently held short.
However Vericel Corporation's short interest can also be evaluated against the total number of Vericel Corporation shares, or, against the total number of tradable Vericel Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vericel Corporation's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Vericel Corporation shares in existence, roughly 90 shares are currently held short) or 0.0934% of the tradable shares (for every 100,000 tradable Vericel Corporation shares, roughly 93 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vericel Corporation.
Find out more about how you can short Vericel Corporation stock.
We're not expecting Vericel Corporation to pay a dividend over the next 12 months.
Vericel Corporation's shares were split on a 1:20 basis on 16 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vericel Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Vericel Corporation shares which in turn could have impacted Vericel Corporation's share price.
Over the last 12 months, Vericel Corporation's shares have ranged in value from as little as $6.78 up to $26.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vericel Corporation's is 3.0581. This would suggest that Vericel Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.